Eli Lilly and Company (LLY.SW)
| Previous close | 745.00 |
| Open | 750.00 |
| Bid | 740.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 750.00 - 750.00 |
| 52-week range | 386.00 - 750.00 |
| Volume | |
| Avg. volume | 571 |
| Market cap | 716.947B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 122.75 |
| EPS (TTM) | 6.11 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 4.71 (0.63%) |
| Ex-dividend date | 15 May 2024 |
| 1y target est | N/A |
PR NewswireMelissa Seymour to join Lilly as executive vice president of Global Quality
Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024. Seymour currently serves as the chief quality officer for Bristol Myers Squibb and succeeds Johna Norton, whose retirement after 34 years of service was announced earlier this year.
BenzingaEli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
On Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli Lilly and Co. (NYSE:LLY). QurAlis has granted Lilly global rights to develop and commercialize QRL-204, a splice-switching antisense oligonucleotide (ASO) designed to restore UNC13A function in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Under the terms of the agreement, QurAlis granted Lilly an exclusive, worldwide license to develop an
Investor's Business DailyBeyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight
As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.
